Functionally, suppression of FGFR4 through this splicing-dependent mechanism impairs HCC cell proliferation, migration, and clonogenicity, suggesting that modulation of the SNRPE–FGFR4 axis may offer therapeutic benefit. The gene discussed is FGFR4; the disease is hepatocellular carcinoma.